Instructions for Sermion (Nicergoline) pills
English product name
Sermion®
Release form
tabb, shell, 5 mg: 30 pcs
Description:
The tablets, covered with an orange shell, are round, convex.
1 tab.
nitergolin 5 mg
Auxiliary substances:
calcium hydrophosphate dihydrate - 100 mg,
cellulose microcrystalline - 22.4 mg,
magnesium stearate - 1.3 mg,
sodium carboxymethyl cellulose - 1.3 mg.
Composition of sugar shell:
- sucrose - 33.35 mg,
- talc - 10.9 mg
- acacia resin - 2.7 mg,
- sandarak resin - 1 mg,
- magnesium carbonate - 0.7 mg,
- titanium dioxide (E171) - 0.7 mg,
- canifol - 0.6 mg,
- carnauba wax - 0.06 mg,
- sunset yellow (E110) - 0.05 mg.
ATC codes
C04AE02 Nicergoline
Clinical-pharmacological groups / Group affiliation
Alpha-adrenolocator. A drug Sermion that improves cerebral and peripheral blood circulation
Active substance Sermion
nitergolin
Pharmacotherapy group:
Alpha Adrenolocator
Storage Conditions:
The drug Sermion should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years.
Testimony Sermion:
acute and chronic cerebral metabolic and vascular disorders (due to atherosclerosis, arterial hypertension, thrombosis or cerebral vessel embolism, including acute transitory cerebral circulation disorder, vascular dementia (30 mg tablets should be used) and headaches caused by vasospasm);
acute and chronic peripheral metabolic and vascular disorders (organic and functional limb arteriopathy, Reynaud's disease, syndromes caused by peripheral blood flow disorder).
Method of use, course and dosage Nicergoline:
The preparation is administered orally at 5-10 mg three times/day or at 30 mg twice/day, at equal intervals of time, for a long time.
For chronic disorders of cerebral circulation, vascular cognitive disorders, post-stroke conditions Sermion® is prescribed 10 mg three times/day. The therapeutic effect of the preparation develops gradually, and the course of treatment should be at least 3 months.
Pharmacological effect Sermion:
A drug Sermion that improves cerebral and peripheral blood circulation, alpha-adrenolocator.
Nitsergolin is a derivative of ergolin that improves metabolic and hemodynamic processes in the brain. It reduces platelet aggregation and improves the rheological properties of the blood, increasing the rate of blood flow in the upper and lower extremities. It has an alpha-1-adrenolocising effect, which causes an improvement in blood flow. It has a direct effect on cerebral neurotransmitters (noradrenergic, dopaminergic and acetylcholinergic), increasing their activity, which contributes to the optimization of cognitive processes.
Use in children Nicergoline
The use of the preparation in children and adolescents under 18 years of age is contraindicated.
- Nosology (ICD codes)
- F01
- Vascular dementia
- G45
- Transitory cerebral ischemic attacks [attacks] and related syndromes
- I10
- Essential [primary] hypertension
- I63
- Brain infarction
- I67.2
- Cerebral atherosclerosis
- I69
- Effects of cerebrovascular disease
- I73.0
- Reynaud syndrome
- I73.1
- Clotting Thrombangitis [Berger's disease]
- I73.8
- Other specified diseases of peripheral vessels
- I73.9
- Peripheral vascular disease unspecified (including interspersed lameness, arterial spasm)
- I74
- Blood embolism and blood thrombosis
- I79.2
- Peripheral angiopathy for diseases classified in other headings (including diabetic angiopathy)
- R51
- Headache
